# Engineered exosomes as drug carriers

Source: https://onco.cc/technologies/exosome-therapeutics/  
OnCo record `exosome-therapeutics` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Loading the tiny vesicles cells naturally use to talk to each other with a cancer drug, so the body treats the carrier as its own.

## Summary

Exosomes are natural lipid vesicles that cross biological barriers and are poorly cleared by the immune system. The best-known oncology example is iExosomes, mesenchymal-cell exosomes loaded with siRNA against KRAS G12D, in a phase 1 in pancreatic cancer at MD Anderson (NCT03608631). Manufacturing consistency, loading efficiency and potency per particle are the barriers; no exosome therapeutic has been approved.

## Fields

- Kind: Technology
- Status: phase-1
- Last checked: 2026-09-08
- Tags: frontier; promising
- Principle: Donor cells are engineered or exosomes are loaded ex vivo with siRNA, protein or small molecules; surface proteins such as CD47 reduce clearance and can be modified for targeting.
- Strengths: Low immunogenicity and long circulation; Crosses barriers that liposomes struggle with; Can carry nucleic acids that need protection
- Limitations: Manufacturing scale and batch consistency; Low and variable drug loading; Biodistribution still favours liver and spleen

## Sources

- iExosomes phase 1 (NCT03608631): https://clinicaltrials.gov/study/NCT03608631

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Exosome injections](https://onco.cc/technologies/rejuv-frontier-exosome-injections/), [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/), [Oligonucleotide therapeutics](https://onco.cc/technologies/antisense-sirna/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/)
- roadmaps: [Radical oncology: what could change the war by 2035](https://onco.cc/roadmaps/frontier-2035/)
- pathways: [The pre-metastatic niche](https://onco.cc/pathways/pre-metastatic-niche/)

---
JSON: https://onco.cc/api/v1/entities/exosome-therapeutics.json